Bulletin
Investor Alert

Market Pulse Archives

Sept. 20, 2021, 7:16 a.m. EDT

Pfizer and BioNTech say COVID-19 vaccine safe and effective in children aged 5 to 11

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)
  • X
    SPDR S&P Biotech ETF (XBI)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Pfizer Inc. /zigman2/quotes/202877789/composite PFE +0.70% and German partner BioNTech SE /zigman2/quotes/214419716/composite BNTX -2.80% on Monday announced positive results in a Phase 2/3 trial of their COVID-19 vaccine in children aged 5 to 11, and said the vaccine was safe, well tolerated and produced "robust" neutralizing antibody response. The companies said participants in the trial were given a two-dose regimen of 10 ug administered 21 days apart, a smaller dose than the 30 ug given to people aged 12 and older. "The antibody responses in the participants given 10 ug doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 ug doses," the companies said in a joint statement. "The 10 ug dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. These are the first results from a pivotal trial of a COVID-19 vaccine in this age group." The companies are planning to submit the data to the Food and Drug Administration and the European Medicines Agency, as well as to other regulators around the world as soon as possible. Results from a trial involving children younger than 5 are expected "as soon as later this year," said the statement. "Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. -- underscoring the public health need for vaccination," said Pfizer CEO Albert Bourla in the statement. There were 2,268 participants in the trial. Shares of both companies were lower premarket, caught up in a broad market rout sparked by fears of a default by Chinese property developer China Evergrande. Pfizer shares have gained 19% in the year to date, while BioNTech has gained 341%. The SPDR S&P Biotech ETF /zigman2/quotes/205950134/composite XBI +0.27% has fallen 6% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.11% has gained 18%.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 43.16
+0.30 +0.70%
Volume: 17.18M
Oct. 22, 2021 4:02p
P/E Ratio
18.48
Dividend Yield
3.61%
Market Cap
$240.30 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 278.34
-8.02 -2.80%
Volume: 3.56M
Oct. 22, 2021 4:00p
P/E Ratio
14.61
Dividend Yield
N/A
Market Cap
$69.45 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/205950134/composite
US : U.S.: NYSE Arca
$ 124.18
+0.34 +0.27%
Volume: 6.44M
Oct. 22, 2021 4:00p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,544.90
-4.88 -0.11%
Volume: 1.82B
Oct. 22, 2021 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.